All sponsors

Madrigal Pharmaceuticals, Inc. $MDGL

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-33
RECRUITING2
READOUTS ≤12 MONTHS2
Open Madrigal Pharmaceuticals, Inc. on the live radar map → 📅 $MDGL readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Resmetirom
NCT05500222
P3Active, not recruitingNASH; Cirrhosis, Liver8452026-12 (+16 mo)
Resmetirom
NCT04951219
P3Active, not recruitingNon-Alcoholic Fatty Liver Disease8102027-03 (+51 mo)
MAESTRO-NASH
NCT03900429
P3Active, not recruitingNASH - Nonalcoholic Steatohepatitis17592028-01 (+78 mo)
Resmetirom
NCT07335601
P2RecruitingMASH - Metabolic Dysfunction-Associated Steatohepatitis1202028-08
Resmetirom
NCT07763015
P2RecruitingMASH; MASH - Metabolic Dysfunction-Associated Steatohepatitis612029-07